Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3 study of pomalidomide + cyclophosphamide + dexamethasone versus pomalidomide + dexamethasone in relapsed or refractory multiple myeloma (AMN study)
KCT0003261Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide, cyclophosphamide, dexamethasone in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2019; status: completed.
02
Drugs
pomalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0003261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003261.